Cargando…

Poly(HydroxyButyrate-co-HydroxyValerate) (PHBHV) Nanocarriers for Silymarin Release as Adjuvant Therapy in Colo-rectal Cancer

The aim of this study was to address one of the major challenges of the actual era of nanomedicine namely, the bioavailability of poorly water soluble drugs such as Silymarin. We developed new, biodegradable, and biocompatible nanosized shuttles for Silymarin targeted delivery in colon-cancer cells....

Descripción completa

Detalles Bibliográficos
Autores principales: Radu, Ionut-Cristian, Hudita, Ariana, Zaharia, Catalin, Stanescu, Paul O., Vasile, Eugenia, Iovu, Horia, Stan, Miriana, Ginghina, Octav, Galateanu, Bianca, Costache, Marieta, Langguth, Peter, Tsatsakis, Aristidis, Velonia, Kelly, Negrei, Carolina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5539237/
https://www.ncbi.nlm.nih.gov/pubmed/28824432
http://dx.doi.org/10.3389/fphar.2017.00508
_version_ 1783254449008934912
author Radu, Ionut-Cristian
Hudita, Ariana
Zaharia, Catalin
Stanescu, Paul O.
Vasile, Eugenia
Iovu, Horia
Stan, Miriana
Ginghina, Octav
Galateanu, Bianca
Costache, Marieta
Langguth, Peter
Tsatsakis, Aristidis
Velonia, Kelly
Negrei, Carolina
author_facet Radu, Ionut-Cristian
Hudita, Ariana
Zaharia, Catalin
Stanescu, Paul O.
Vasile, Eugenia
Iovu, Horia
Stan, Miriana
Ginghina, Octav
Galateanu, Bianca
Costache, Marieta
Langguth, Peter
Tsatsakis, Aristidis
Velonia, Kelly
Negrei, Carolina
author_sort Radu, Ionut-Cristian
collection PubMed
description The aim of this study was to address one of the major challenges of the actual era of nanomedicine namely, the bioavailability of poorly water soluble drugs such as Silymarin. We developed new, biodegradable, and biocompatible nanosized shuttles for Silymarin targeted delivery in colon-cancer cells. The design of these 100 nm sized carrier nanoparticles was based on natural polymers and their biological properties such as cellular uptake potential, cytotoxicity and 3D penetrability were tested using a colon cancer cell line (HT-29) as the in vitro culture model. Comparative scanning electron microscopy (SEM) and atomic force microscopy (AFM) measurements demonstrated that the Silymarin loaded Poly(3-HydroxyButyrate-co-3-HydroxyValerate) (PHBHV) nanocarriers significantly decreased HT-29 cells viability after 6 and 24 h of treatment. Moreover, in vivo-like toxicity studies on multicellular tumor spheroids showed that the Silymarin loaded PHBHV nanocarriers are able to penetrate 3D micro tumors and significantly reduce their size.
format Online
Article
Text
id pubmed-5539237
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-55392372017-08-18 Poly(HydroxyButyrate-co-HydroxyValerate) (PHBHV) Nanocarriers for Silymarin Release as Adjuvant Therapy in Colo-rectal Cancer Radu, Ionut-Cristian Hudita, Ariana Zaharia, Catalin Stanescu, Paul O. Vasile, Eugenia Iovu, Horia Stan, Miriana Ginghina, Octav Galateanu, Bianca Costache, Marieta Langguth, Peter Tsatsakis, Aristidis Velonia, Kelly Negrei, Carolina Front Pharmacol Pharmacology The aim of this study was to address one of the major challenges of the actual era of nanomedicine namely, the bioavailability of poorly water soluble drugs such as Silymarin. We developed new, biodegradable, and biocompatible nanosized shuttles for Silymarin targeted delivery in colon-cancer cells. The design of these 100 nm sized carrier nanoparticles was based on natural polymers and their biological properties such as cellular uptake potential, cytotoxicity and 3D penetrability were tested using a colon cancer cell line (HT-29) as the in vitro culture model. Comparative scanning electron microscopy (SEM) and atomic force microscopy (AFM) measurements demonstrated that the Silymarin loaded Poly(3-HydroxyButyrate-co-3-HydroxyValerate) (PHBHV) nanocarriers significantly decreased HT-29 cells viability after 6 and 24 h of treatment. Moreover, in vivo-like toxicity studies on multicellular tumor spheroids showed that the Silymarin loaded PHBHV nanocarriers are able to penetrate 3D micro tumors and significantly reduce their size. Frontiers Media S.A. 2017-08-02 /pmc/articles/PMC5539237/ /pubmed/28824432 http://dx.doi.org/10.3389/fphar.2017.00508 Text en Copyright © 2017 Radu, Hudita, Zaharia, Stanescu, Vasile, Iovu, Stan, Ginghina, Galateanu, Costache, Langguth, Tsatsakis, Velonia and Negrei. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Radu, Ionut-Cristian
Hudita, Ariana
Zaharia, Catalin
Stanescu, Paul O.
Vasile, Eugenia
Iovu, Horia
Stan, Miriana
Ginghina, Octav
Galateanu, Bianca
Costache, Marieta
Langguth, Peter
Tsatsakis, Aristidis
Velonia, Kelly
Negrei, Carolina
Poly(HydroxyButyrate-co-HydroxyValerate) (PHBHV) Nanocarriers for Silymarin Release as Adjuvant Therapy in Colo-rectal Cancer
title Poly(HydroxyButyrate-co-HydroxyValerate) (PHBHV) Nanocarriers for Silymarin Release as Adjuvant Therapy in Colo-rectal Cancer
title_full Poly(HydroxyButyrate-co-HydroxyValerate) (PHBHV) Nanocarriers for Silymarin Release as Adjuvant Therapy in Colo-rectal Cancer
title_fullStr Poly(HydroxyButyrate-co-HydroxyValerate) (PHBHV) Nanocarriers for Silymarin Release as Adjuvant Therapy in Colo-rectal Cancer
title_full_unstemmed Poly(HydroxyButyrate-co-HydroxyValerate) (PHBHV) Nanocarriers for Silymarin Release as Adjuvant Therapy in Colo-rectal Cancer
title_short Poly(HydroxyButyrate-co-HydroxyValerate) (PHBHV) Nanocarriers for Silymarin Release as Adjuvant Therapy in Colo-rectal Cancer
title_sort poly(hydroxybutyrate-co-hydroxyvalerate) (phbhv) nanocarriers for silymarin release as adjuvant therapy in colo-rectal cancer
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5539237/
https://www.ncbi.nlm.nih.gov/pubmed/28824432
http://dx.doi.org/10.3389/fphar.2017.00508
work_keys_str_mv AT raduionutcristian polyhydroxybutyratecohydroxyvaleratephbhvnanocarriersforsilymarinreleaseasadjuvanttherapyincolorectalcancer
AT huditaariana polyhydroxybutyratecohydroxyvaleratephbhvnanocarriersforsilymarinreleaseasadjuvanttherapyincolorectalcancer
AT zahariacatalin polyhydroxybutyratecohydroxyvaleratephbhvnanocarriersforsilymarinreleaseasadjuvanttherapyincolorectalcancer
AT stanescupaulo polyhydroxybutyratecohydroxyvaleratephbhvnanocarriersforsilymarinreleaseasadjuvanttherapyincolorectalcancer
AT vasileeugenia polyhydroxybutyratecohydroxyvaleratephbhvnanocarriersforsilymarinreleaseasadjuvanttherapyincolorectalcancer
AT iovuhoria polyhydroxybutyratecohydroxyvaleratephbhvnanocarriersforsilymarinreleaseasadjuvanttherapyincolorectalcancer
AT stanmiriana polyhydroxybutyratecohydroxyvaleratephbhvnanocarriersforsilymarinreleaseasadjuvanttherapyincolorectalcancer
AT ginghinaoctav polyhydroxybutyratecohydroxyvaleratephbhvnanocarriersforsilymarinreleaseasadjuvanttherapyincolorectalcancer
AT galateanubianca polyhydroxybutyratecohydroxyvaleratephbhvnanocarriersforsilymarinreleaseasadjuvanttherapyincolorectalcancer
AT costachemarieta polyhydroxybutyratecohydroxyvaleratephbhvnanocarriersforsilymarinreleaseasadjuvanttherapyincolorectalcancer
AT langguthpeter polyhydroxybutyratecohydroxyvaleratephbhvnanocarriersforsilymarinreleaseasadjuvanttherapyincolorectalcancer
AT tsatsakisaristidis polyhydroxybutyratecohydroxyvaleratephbhvnanocarriersforsilymarinreleaseasadjuvanttherapyincolorectalcancer
AT veloniakelly polyhydroxybutyratecohydroxyvaleratephbhvnanocarriersforsilymarinreleaseasadjuvanttherapyincolorectalcancer
AT negreicarolina polyhydroxybutyratecohydroxyvaleratephbhvnanocarriersforsilymarinreleaseasadjuvanttherapyincolorectalcancer